Physician profile
Tomas Ayala
NPI 1639108145
$7,209.29
in general payments reported to CMS, 2019-2025
36 companies · $791 in 2025
The $791 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $546 · 2020: $231 · 2021: $926 · 2022: $1,639 · 2023: $1,482 · 2024: $1,593 · 2025: $791.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,866.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,866.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,191.01 | 2021-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Jot Dx, Tendril |
| Novartis Pharmaceuticals Corporation | $1,084.48 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $419.54 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $362.11 | 2020-2025 | Farxiga, Brilinta |
| Pfizer INC. | $361.56 | 2019-2025 | |
| Boston Scientific Corporation | $335.78 | 2019-2023 | Watchman, Bodyguardian |
| Novo Nordisk INC | $317.76 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Medtronic, INC. | $317.23 | 2021-2024 | Onyx Frontier |
| Janssen Pharmaceuticals, INC | $268.41 | 2020-2024 | Xarelto |
| Daiichi Sankyo INC. | $263.52 | 2023-2024 | Injectafer |
| Amgen INC. | $233.23 | 2019-2025 | Repatha, Repatha |
| Kowa Pharmaceuticals America, INC. | $203.38 | 2021-2022 | |
| Kestra Medical Technology Services, INC. | $184.92 | 2023-2024 | Assure Wcd |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $169.58 | 2019-2022 | |
| Amarin Pharma, INC. | $153.62 | 2019-2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $147.25 | 2023-2025 | |
| Baxter Healthcare | $127.57 | 2024-2025 | Hillrom - Cardiac Ambulatory Monitor, Hillrom - Carnation Ambulatory Monitor |
| Atricure, INC. | $122.45 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $121.56 | 2019-2024 | Verquvo |
| Sanofi-Aventis U.S. LLC | $117.49 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $110.26 | 2023-2025 | Camzyos, Eliquis |
| Edwards Lifesciences Corporation | $97.10 | 2019 | |
| Philips North America LLC | $81.59 | 2023-2024 | (5091) Amb Mon & Diag Und |
| Lantheus Medical Imaging, INC. | $56.09 | 2023-2024 | Definity |
| Abiomed | $52.61 | 2024 | Impella |
| Irhythm Technologies, INC. | $50.96 | 2022-2024 | Zio Monitor, Zio Xt Patch |
| Esperion Therapeutics, INC. | $44.06 | 2025 | Nexletol |
| Lilly USA, LLC | $41.33 | 2019-2023 | Mounjaro, Trulicity |
| Regeneron Healthcare Solutions, INC. | $31.08 | 2020-2022 | |
| Genzyme Corporation | $27.89 | 2022 | |
| Alnylam Pharmaceuticals INC. | $25.42 | 2024 | Onpattro |
| Astellas Pharma US INC | $24.36 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $21.80 | 2023 | Inpefa |
| Kiniksa Pharmaceuticals International, Plc | $18.16 | 2024 | Arcalyst |
| Sunovion Pharmaceuticals INC. | $12.91 | 2019 | |
| Itamar Medical INC | $11.22 | 2023 | Watchpatone |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tomas Ayala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.